Skip to content

Red flags and safety concerns

TL;DR — A high BP number alone is not a hypertensive emergency; emergency means severe pressure elevation with acute target-organ injury. The dangerous HHD presentations are acute pulmonary edema, myocardial ischemia/injury, neurologic deficit/encephalopathy, aortic catastrophe, renal injury, malignant-hypertension microangiopathy and unstable arrhythmia (Siddiqi 2023, PMID 37421281; Boulestreau 2024, PMID 38658108). Conversely, rapid unsupervised lowering in severe asymptomatic hypertension can cause harm. Chronic-treatment hazards include hypotension/syncope, AKI, electrolyte disturbance, hyperkalemia, bradycardia and drug interactions; intensive targets increase several of these events (SPRINT 2021, PMID 34010531). This page describes research and safety boundaries, not individualized emergency instructions.

1. Emergency is organ injury, not a number

State BP Acute target-organ injury Evidence-based distinction
Transient elevation High None demonstrated Pain, anxiety, technique and context matter
Severe asymptomatic elevation Often very high None demonstrated Usually not an indication for abrupt IV lowering
Hypertensive emergency Often very high Present Controlled condition-specific reduction and monitoring
Malignant hypertension Severe Retinopathy/microangiopathy and multiorgan injury phenotype Systemic vascular disease

Emergency definitions and outcomes vary across studies, which complicates pooled incidence and mortality estimates (Astarita 2020, PMID 32510905; Siddiqi 2023, PMID 37421281).

The EDEN-47 analysis puts numbers on how uncommon and how heterogeneous the presentation is in older adults. Across a one-week recruitment of all patients aged ≥65 attending the emergency departments of 52 Spanish public hospitals (25,557 patients, covering 19.3% of the Spanish population), 186 hypertensive crises occurred — 0.73% of visits (95% CI 0.63–0.84), corresponding to an estimated annual rate of 429 per 100,000 older inhabitants (371–493). Crises were more frequent in women than men (0.87% versus 0.56%; OR for men 0.64, 0.47–0.87). Acute hospitalization and intensive-care use were 7.5% and 0.5%, respectively, and in-hospital death occurred in 2 of 186 (1.1%); 57.9% had a combined adverse event (ED revisit, hospitalization or death) within one year, and the adjusted one-year hazard was higher in men (HR 1.61, 1.01–2.57) (Miró 2026, PMID 42664163).

Two cautions on reading it: 88.2% of these patients had previously known hypertension and 22% carried an additional acute diagnosis alongside the crisis, so "hypertensive crisis" in routine emergency coding is a mixed category rather than a clean phenotype. The dissociation between benign in-hospital course and a majority one-year adverse-event rate is the operationally useful finding — the crisis visit is a risk marker warranting follow-up, not an event whose treatment ends at discharge.

2. Acute target-organ syndromes

Syndrome Red-flag evidence Why HHD matters
Acute pulmonary edema Severe dyspnea, hypoxemia, congestion Stiff LV/high afterload can decompensate abruptly
Acute coronary syndrome Ischemic symptoms/ECG/troponin dynamics LVH/microvascular disease complicates interpretation
Encephalopathy Altered cognition, seizure, visual symptoms Autoregulatory failure
Stroke/ICH Focal neurologic deficit or hemorrhage BP strategy depends on stroke subtype/timing
Aortic syndrome Abrupt severe chest/back pain, pulse/perfusion difference Pressure and aortic disease interact
Acute kidney injury Creatinine/urine change in clinical context Cause and consequence of severe pressure
Retinal/microangiopathic injury Papilledema, hemorrhage, hemolysis/thrombocytopenia Malignant-hypertension phenotype
Unstable arrhythmia Syncope, ischemia, hypotension, HF AF/VT can precipitate failure

These syndromes have different pressure-reduction pace, agents and endpoint monitoring; one generic emergency target is unsafe (Watson 2018, PMID 29884955; Jones 2025, PMID 40815242).

3. Acute pulmonary edema

The severe-hypertension pulmonary-edema phenotype can reflect rapid afterload redistribution more than slow total-volume accumulation. Vasodilation and ventilatory support are mechanistically central in appropriate acute-care settings; evidence for high-dose nitrate strategies includes small observational studies rather than definitive large trials (Mathew 2021, PMID 34215472).

Assessment Purpose
Oxygenation/ventilation Define respiratory failure
Bedside echo/lung imaging Congestion, EF, valve and alternative cause
ECG/troponin Ischemia and injury
Creatinine/electrolytes Baseline risk and treatment safety
Trigger review AF, ischemia, medication lapse, renal change, infection

“Flash” edema should also raise suspicion for renovascular disease, acute mitral disease or ischemia rather than automatic attribution to chronic HHD.

4. Malignant hypertension

Modern reviews treat malignant hypertension as a systemic cardiovascular disease involving endothelial injury, thrombotic microangiopathy, retinal injury, kidney disease, brain and heart rather than simply an extreme reading (Boulestreau 2024, PMID 38658108).

The absence of one classic retinal sign does not make acute multiorgan injury benign, and chronic severe hypertension can shift autoregulation such that precipitous reduction threatens perfusion.

5. Neurologic presentations

Presentation Safety principle
Ischemic stroke Reperfusion eligibility and acute stroke protocol govern pressure strategy
Intracerebral hemorrhage Hemorrhage-specific target and timing evidence
Encephalopathy/PRES Controlled reduction with neurologic monitoring
Seizure/altered mental status Do not assume hypertension is the sole cause

Chronic targets from SPRINT, STEP or guidelines must not be imported into acute stroke management (SPS3 2013, PMID 23726159; Jones 2025, PMID 40815242).

6. Myocardial injury and ECG complexity

LVH can produce repolarization abnormalities that complicate ischemia assessment; troponin can rise from supply–demand mismatch, HF, CKD or acute coronary thrombosis. Dynamic clinical, ECG, biomarker and imaging evidence is therefore required.

A negative ECG-LVH result also does not exclude anatomical hypertrophy, given low sensitivity (Pewsner 2007, PMID 17726091).

7. Syncope and arrhythmia red flags

Finding Concern
Exertional syncope Outflow obstruction, ischemia, arrhythmia, severe valve disease
Syncope with palpitations Tachy-/bradyarrhythmia
Family history of sudden death Inherited cardiomyopathy/channel disease
Documented sustained VT Scar/ischemia/cardiomyopathy evaluation
AF with instability Acute rate/rhythm and thromboembolic framework

HHD should not be used to explain asymmetric hypertrophy or syncope without considering HCM and infiltrative disease; CMR discriminators overlap at patient level (Zhao 2024, PMID 39156132).

AF diagnosis and anticoagulation/rhythm management follow AF guidance, not HHD status alone (Joglar 2024, PMID 38033089).

8. Intensive-treatment adverse events

SPRINT found lower events and mortality with intensive treatment but significantly more hypotension, syncope, electrolyte abnormalities and AKI/failure (SPRINT 2015, PMID 26551272; SPRINT 2021, PMID 34010531).

ACCORD BP reported treatment-attributed serious adverse events in 3.3% with intensive versus 1.3% with standard treatment (ACCORD 2010, PMID 20228401).

Among adults >60 pooled across SPRINT, STEP and ACCORD BP, intensive treatment increased hypotension HR 1.46 (95% CI 1.12–1.91) and syncope HR 1.43 (1.06–1.93) (Li 2023, PMID 37099984).

Harm Monitoring/interpretation issue
Symptomatic hypotension Symptoms and standing BP, not number alone
Syncope Arrhythmia/structural causes also require evaluation
AKI/eGFR fall Hemodynamic change versus intrinsic injury/congestion
Hyponatremia/hypokalemia Diuretic dose, intake and interactions
Hyperkalemia RAAS/MRA, CKD, supplements and acute illness
Bradycardia Beta-blocker/non-DHP CCB and conduction disease

Orthostatic hypotension is associated with cardiovascular risk and can be both disease marker and treatment harm (Fedorowski 2019, PMID 31713533).

9. Kidney-function changes

In SPS3, the lower BP target accelerated early eGFR decline; rapid decline occurred in 24% versus 19%, OR 1.4 (95% CI 1.1–1.6), while later slopes converged (Peralta 2016, PMID 26762524).

This illustrates why a creatinine change cannot be labeled uniformly beneficial “hemodynamic dip” or harmful AKI without timing, magnitude, volume, medication and outcomes.

10. Potassium and MRA safety

TOPCAT doubled hyperkalemia (18.7% vs 9.1%) with spironolactone and raised creatinine, despite reduced HF hospitalization (Pitt 2014, PMID 24716680).

RALES showed mortality benefit in severe HFrEF under trial monitoring; post-trial application requires renal and potassium safety infrastructure (Pitt 1999, PMID 10471456).

Primary aldosteronism treatment can require higher MRA intensity than ordinary hypertension, increasing the importance of cause-specific expertise and monitoring (Adler 2025, PMID 40658480).

11. RAAS-blocker safety

Concern Context
Creatinine rise Hemodynamic effect, CKD, volume depletion, renal artery disease
Hyperkalemia CKD, MRA, potassium salt/supplements, acute illness
Angioedema ACE inhibitor; emergency when airway involved
Cough ACE inhibitor tolerability
Pregnancy RAAS blockade has fetal toxicity and requires a different framework
Dual RAAS blockade More adverse renal/electrolyte effects without routine benefit

12. Inpatient asymptomatic elevated BP

A systematic review of inpatient elevated-BP guidelines found inconsistent recommendations and limited evidence for managing asymptomatic readings (Wilson 2024, PMID 38560900).

Hospital pain, sleep disruption, medications, fluid shifts and measurement technique can transiently elevate BP. Rapid reactive treatment without organ injury can produce hypotension and distract from reliable outpatient reassessment.

13. Renal-denervation safety and expectations

SYMPLICITY HTN-3 showed no significant sham-adjusted efficacy at six months (Bhatt 2014, PMID 24678939). Newer sham-controlled meta-analysis supports modest BP reduction without established HHD event prevention (Vukadinović 2024, PMID 39355923).

Meta-analyses track renal-artery complications, kidney function and major adverse events, but rare/late safety and clinical benefit require longer surveillance (Stavropoulos 2020, PMID 32049436).

14. Medication and substance review

Exposure HHD safety issue
NSAIDs BP rise, sodium retention, renal interaction
Sympathomimetics/stimulants Pressure and arrhythmia
Glucocorticoids Pressure, volume and metabolic effects
Licorice Mineralocorticoid-like hypertension/hypokalemia
Potassium salt/supplements Hyperkalemia with CKD/RAAS blockade
Alcohol binges BP variability and AF
Abrupt clonidine/beta-blocker withdrawal Rebound or adrenergic risk

15. Re-evaluation triggers in established HHD

  • New exertional chest discomfort, syncope or unexplained functional decline.
  • New AF, sustained ventricular arrhythmia or conduction disease.
  • Rapid increase in wall thickness, new scar or EF decline.
  • Disproportionate LVH, family history or extracardiac infiltrative/genetic clues.
  • Sudden loss of BP control, hypokalemia or renal deterioration.
  • Recurrent pulmonary edema or resistant nighttime hypertension.

HF and hypertension guidelines support etiologic reassessment when the phenotype changes (Heidenreich 2022, PMID 35363499; McDonagh 2021, PMID 34447992; McEvoy 2024, PMID 39210715).

Open questions

  • Which severe asymptomatic inpatient BP elevations benefit from immediate treatment rather than standardized reassessment? (Wilson 2024, PMID 38560900)
  • Can biomarkers distinguish harmful AKI from reversible hemodynamic eGFR change during intensive control? (Peralta 2016, PMID 26762524)
  • What long-term renal-artery and cardiovascular surveillance is required after denervation? (Vukadinović 2024, PMID 39355923)
  • Which HHD phenotypes are at greatest risk of acute afterload-driven pulmonary edema? (Siddiqi 2023, PMID 37421281)
  • Does structured post-discharge follow-up after a hypertensive-crisis emergency visit reduce the high one-year revisit, hospitalization and death rate? (Miró 2026, PMID 42664163)

References

  1. Siddiqi TJ, et al. Clinical Outcomes in Hypertensive Emergency: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2023;12:e029355. PMID 37421281
  2. Boulestreau R, et al. Malignant Hypertension:A Systemic Cardiovascular Disease: JACC Review Topic of the Week. J Am Coll Cardiol. 2024;83:1688-1701. PMID 38658108
  3. SPRINT Research Group. Final Report of a Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2021;384:1921-1930. PMID 34010531
  4. Astarita A, et al. Hypertensive emergencies and urgencies in emergency departments: a systematic review and meta-analysis. J Hypertens. 2020;38:1203-1210. PMID 32510905
  5. Watson K, et al. Focused Update on Pharmacologic Management of Hypertensive Emergencies. Curr Hypertens Rep. 2018;20:56. PMID 29884955
  6. Jones DW, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2025;86:1567-1678. PMID 40815242
  7. Mathew R, et al. High-Dose Nitroglycerin Bolus for Sympathetic Crashing Acute Pulmonary Edema: A Prospective Observational Pilot Study. J Emerg Med. 2021;61:271-277. PMID 34215472
  8. SPS3 Study Group. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet. 2013;382:507-15. PMID 23726159
  9. Pewsner D, et al. Accuracy of electrocardiography in diagnosis of left ventricular hypertrophy in arterial hypertension: systematic review. BMJ. 2007;335:711. PMID 17726091
  10. Zhao Q, et al. Cardiac magnetic resonance imaging for discrimination of hypertensive heart disease and hypertrophic cardiomyopathy: a systematic review and meta-analysis. Front Cardiovasc Med. 2024;11:1421013. PMID 39156132
  11. Joglar JA, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149:e1-e156. PMID 38033089
  12. SPRINT Research Group. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015;373:2103-16. PMID 26551272
  13. ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575-85. PMID 20228401
  14. Li X, et al. Intensive blood pressure control for patients aged over 60: A meta-analysis of the SPRINT, STEP, and ACCORD BP randomized controlled trials. Maturitas. 2023;172:52-59. PMID 37099984
  15. Fedorowski A, et al. Orthostatic hypotension and cardiovascular risk. Kardiol Pol. 2019;77:1020-1027. PMID 31713533
  16. Peralta CA, et al. Effect of Intensive Versus Usual Blood Pressure Control on Kidney Function Among Individuals With Prior Lacunar Stroke: A Post Hoc Analysis of the Secondary Prevention of Small Subcortical Strokes (SPS3) Randomized Trial. Circulation. 2016;133:584-91. PMID 26762524
  17. Pitt B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383-92. PMID 24716680
  18. Pitt B, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-17. PMID 10471456
  19. Adler GK, et al. Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2025;110:2453-2495. PMID 40658480
  20. Wilson LM, et al. Management of Inpatient Elevated Blood Pressures : A Systematic Review of Clinical Practice Guidelines. Ann Intern Med. 2024;177:497-506. PMID 38560900
  21. Bhatt DL, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393-401. PMID 24678939
  22. Vukadinović D, et al. Effects of Catheter-Based Renal Denervation in Hypertension: A Systematic Review and Meta-Analysis. Circulation. 2024;150:1599-1611. PMID 39355923
  23. Stavropoulos K, et al. Efficacy and safety of renal denervation for the management of arterial hypertension: A systematic review and meta-analysis of randomized, sham-controlled, catheter-based trials. J Clin Hypertens (Greenwich). 2020;22:572-584. PMID 32049436
  24. Heidenreich PA, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e895-e1032. PMID 35363499
  25. McDonagh TA, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599-3726. PMID 34447992
  26. McEvoy JW, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45:3912-4018. PMID 39210715
  27. Miró Ò, et al. Hypertensive crisis in the elderly: epidemiological, clinical and outcome: EDEN-47 study. Gerontology. 2026;:1-21. PMID 42664163